Biochimica et Biophysica Acta-Reviews on Cancer

Article	Citations
SENP3: Cancers and diseases	341
PAK2 as a therapeutic target in cancer: Mechanisms, challenges, and future perspectives	237
Research progress of mitochondria and cytoskeleton crosstalk in tumour development	223
Adipose tissue-to-breast cancer crosstalk: Comprehensive insights	221
The potential of methioninase for cancer treatment	204
Ponatinib: An update on its drug targets, therapeutic potential and safety	169
The role of 5-HT metabolism in cancer	146
Adenosine in cancer immunotherapy: Taking off on a new plane	140
Emerging roles of PIWI-interacting RNAs (piRNAs) and PIWI proteins in head and neck cancer and their potential clinical implications	134
The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy	118
A comprehensive review of current therapeutic strategies in cancers targeting DNA damage response mechanisms in head and neck squamous cell cancer	99
New horizons in the mechanisms and therapeutic strategies for PD-L1 protein degradation in cancer	98
The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate	96
Editorial Board	96
Extrachromosomal DNA: Redefining the pathogenesis of glioblastoma	89
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective	82
Editorial Board	82
Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma	75
Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy	74
ESR1 activating mutations: From structure to clinical application	73
Editorial Board	72
Targeting nanoparticles to malignant tumors	64
Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy	63
Lymphatic vasculature in ovarian cancer	62
Tumor microenvironment crosstalk between tumors and the nervous system in pancreatic cancer: Molecular mechanisms and clinical perspectives	62

An insight into the ubiquitin-proteasomal axis and related therapeutic approaches towards central nervous system malignancies	61
The naked translation in cancer	60
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy	59
New insights into RAS in head and neck cancer	59
The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models	56
TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance	54
The clinical significance and correlative signaling pathways of paired box gene 9 in development and carcinogenesis	54
Machine Learning in Epigenomics: Insights into Cancer Biology and Medicine	52
Advances and challenges in therapeutic resistant biomarkers of neuroblastoma: A comprehensive review	50
Decoding secret role of mesenchymal stem cells in regulating cancer stem cells and drug resistance	46
Recent advances in understanding the molecular role of phosphoinositide-specific phospholipase C gamma 1 as an emerging onco-driver and novel therapeutic target in human carcinogenesis	45
New advances in the therapeutic strategy of head and neck squamous cell carcinoma: A review of latest therapies and cutting-edge research	45
The role of the NDRG1 in the pathogenesis and treatment of breast cancer	44
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?	44
A Darwinian perspective on tumor immune evasion	43
Targeting protein kinases benefits cancer immunotherapy	43
The role of m6A modification in pediatric cancer	43
Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53	43
A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer	43
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review	42
RNA m6A modification in prostate cancer: A new weapon for its diagnosis and therapy	41
Expression and function of NF-Y subunits in cancer	39
N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy	39
The overall process of metastasis: From initiation to a new tumor	39
The role of nitric oxide synthase/ nitric oxide in infection-related cancers: Beyond antimicrobial activity	38
Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients	38
Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy	38
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids	38
Mitochondrial dynamics, a new therapeutic target for Triple Negative Breast Cancer	37
Decoding PTEN regulation in clear cell renal cell carcinoma: Pathway for biomarker discovery and therapeutic insights	37
Dual roles of human endogenous retroviruses in cancer progression and antitumor immune response	37
Drivers of cancer metastasis – Arise early and remain present	37
Delivery routes matter: Safety and efficacy of intratumoral immunotherapy	37
Targeting autophagy in urological system cancers: From underlying mechanisms to therapeutic implications	37
A digital highway for data fluidity and data equity in precision medicine	36
Ezrin gone rogue in cancer progression and metastasis: An enticing therapeutic target	35
Improving DCIS diagnosis and predictive outcome by applying artificial intelligence	35
The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence	34
Metastasis prevention: How to catch metastatic seeds	34
Targeting ion channels for the treatment of lung cancer	33
Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment	33
Alpha-1 antitrypsin deficiency and primary liver cancers	33
Uveal melanoma modeling in mice and zebrafish	33
MOMP: A critical event in cell death regulation and anticancer treatment	32
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles	32
Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies	31
Retraction notice to “Coagulation and inflammation in cancer: Limitations and prospects for treatment” [Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877 (2022) 188727]	31
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications	31
The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics	30
ETS transcription factors: Multifaceted players from cancer progression to tumor immunity	30

Immunotherapy for HPV negative head and neck squamous cell carcinoma	30
miRNAs and androgen deprivation therapy for prostate cancer	29
Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells	29
Understanding the role of DNA methylation in colorectal cancer: Mechanisms, detection, and clinical significance	29
The interaction of SET and protein phosphatase 2A as target for cancer therapy	29
Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives	28
Glioblastoma preclinical models: Strengths and weaknesses	28
Time to abandon CAR-T monotherapy for solid tumors	28
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies	28
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance	27
The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer	27
Tumoral heterogeneity in neuroblastoma	27
Exploration of tumor penetrating peptide iRGD as a potential strategy to enhance tumor penetration of cancer nanotherapeutics	27
Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer	27
Progress and challenges of immunotherapy in triple-negative breast cancer	27
Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy	27
Targeting the heat shock response induced by modulated electro-hyperthermia (mEHT) in cancer	27
Combinatorial therapy in tumor microenvironment: Where do we stand?	27
Clinical and molecular markers guide the genetics of pheochromocytoma and paraganglioma	27
Understanding and advancement in gold nanoparticle targeted photothermal therapy of cancer	26
The tumor microenvironment's gambit: Exosomal pawns on the board of head and neck cancer	26
New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies	26
An overview of the research progress of BRCA gene mutations in breast cancer	26
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents	26
Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity	25
Mitochondria: The metabolic switch of cellular oncogenic transformation	25
Advances in epigenetic modifications and cervical cancer research	25
Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors	25
Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: An emerging trend in cancer patient care	25
Histone deacetylase complexes: Structure, regulation and function	25
T cell exhaustion in human cancers	25
Genomic instability, inflammatory signaling and response to cancer immunotherapy	25
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy	24
Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapy	24
Nutrition and dietary restrictions in cancer prevention	24
Targeting Trop-2 in cancer: Recent research progress and clinical application	24
GPX4: The hub of lipid oxidation, ferroptosis, disease and treatment	24
Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: From mechanisms to therapeutic targets	24
B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer	23
Editorial Board	23
Editorial Board	23
Neuromedin U in the tumor microenvironment - Possible actions in tumor progression	23
Protein domain-based approaches for the identification and prioritization of therapeutically actionable cancer variants	23
The roles of small extracellular vesicles in lung cancer: Molecular pathology, mechanisms, diagnostics, and therapeutics	22
Editorial Board	22
One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment	22
Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer	22
Targeting glutamine metabolism crosstalk with tumor immune response	22
Oncoviruses: How do they hijack their host and current treatment regimes	22
CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future	22
Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars	22
Recent advances in HDAC-targeted imaging probes for cancer detection	22
Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles	22
Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence	22
Editorial Board	21
Epigenetic modulation by oncolytic viruses: Implications for cancer therapeutic efficacy	21
The intratumoural microbiota in cancer: new insights from inside	21
An overview of kinin mediated events in cancer progression and therapeutic applications	21
Advances in nuclei targeted delivery of nanoparticles for the management of cancer	21
Transcription factors in glioblastoma – Molecular pathogenesis and clinical implications	21
Regulation of cGAS-STING signalling in cancer: Approach for combination therapy	21
Dissecting SOX2 expression and function reveals an association with multiple signaling pathways during embryonic development and in cancer progression	20
Unraveling the role of deubiquitinating enzymes on cisplatin resistance in several cancers	20
Helicobacter pylori triggers inflammation and oncogenic transformation by perturbing the immune microenvironment	20
The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy?	20
Leveraging preclinical models of metastatic breast cancer	20
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes	20
Targeting endothelial cell anergy to improve CAR T cell therapy for solid tumors	19
Corrigendum to “Recent thymic emigrants as the bridge between thymoma and autoimmune diseases” [Biochim Biophys Acta Rev Cancer. 2022;1877(3):188730.]	19
Paradoxical functions of long noncoding RNAs in modulating STAT3 signaling pathway in hepatocellular carcinoma	19
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence	19
Finding the junction between claudins and endometrial carcinoma	19
Promises of natural products as clinical applications for cancer	19
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors	19
Roles of CDK12 mutations in PCa development and treatment	19
Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets	19
How to evaluate deep learning for cancer diagnostics – factors and recommendations	19
Precision oncology: Using cancer genomics for targeted therapy advancements	19
Decoding mitochondria's role in immunity and cancer therapy	19
Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model	19

CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways	19
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway	18
The potential roles of p53 signaling reactivation in pancreatic cancer therapy	18
Keep a watchful eye on methionine adenosyltransferases, novel therapeutic opportunities for hepatobiliary and pancreatic tumours	18
Ability of animals to detect cancer odors	18
Breaking through therapeutic barriers: Insights into CDK4/6 inhibition resistance in hormone receptor-positive metastatic breast cancer	18
Fringe family genes and their modulation of Notch signaling in cancer	18
Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities	17
Belling the “cat”: Wnt/β-catenin signaling and its significance in future cancer therapies	17
Role of the calcium-sensing receptor (CaSR) in cancer metastasis to bone: Identifying a potential therapeutic target	17
RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling	17
YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers	17
Clusterin as modulator of carcinogenesis: A potential avenue for targeted cancer therapy	17
The O-GlcNAcylation and its promotion to hepatocellular carcinoma	17
Core services that power AI-driven transformation in cancer research and care	17